The American Brachytherapy Society Consensus Statement for Permanent Implant Brachytherapy Using Yttrium-90 Microsphere Radioembolization for Liver Tumors

Overview

Journal Brachytherapy

Specialty Radiology

Date 2022 May 22

PMID 35599080

Authors

Navesh K Sharma

S Cheenu Kappadath

Michael Chuong

Michael Folkert

Peter Gibbs

Salma K Jabbour

D Rohan Jeyarajah

Andrew Kennedy

David Liu

Joshua E Meyer

Justin Mikell

Rahul S Patel

Gary Yang

Firas Mourtada

Affiliations

Soon will be listed here.

Abstract

Purpose: To develop a multidisciplinary consensus for high quality multidisciplinary implementation of brachytherapy using Yttrium-90 (Y) microspheres transarterial radioembolization (Y TARE) for primary and metastatic cancers in the liver.

Methods And Materials: Members of the American Brachytherapy Society (ABS) and colleagues with multidisciplinary expertise in liver tumor therapy formulated guidelines for Y TARE for unresectable primary liver malignancies and unresectable metastatic cancer to the liver. The consensus is provided on the most recent literature and clinical experience.

Results: The ABS strongly recommends the use of Y microsphere brachytherapy for the definitive/palliative treatment of unresectable liver cancer when recommended by the multidisciplinary team. A quality management program must be implemented at the start of Y TARE program development and follow-up data should be tracked for efficacy and toxicity. Patient-specific dosimetry optimized for treatment intent is recommended when conducting Y TARE. Implementation in patients on systemic therapy should account for factors that may enhance treatment related toxicity without delaying treatment inappropriately. Further management and salvage therapy options including retreatment with Y TARE should be carefully considered.

Conclusions: ABS consensus for implementing a safe Y TARE program for liver cancer in the multidisciplinary setting is presented. It builds on previous guidelines to include recommendations for appropriate implementation based on current literature and practices in experienced centers. Practitioners and cooperative groups are encouraged to use this document as a guide to formulate their clinical practices and to adopt the most recent dose reporting policies that are critical for a unified outcome analysis of future effectiveness studies.

Citing Articles

Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs.

Bilski M, Peszynska-Piorun M, Konat-Baska K, Brzozowska A, Korab K, Wojtyna E Front Oncol. 2024; 14:1478872.

PMID: 39558956 PMC: 11570579. DOI: 10.3389/fonc.2024.1478872.

Quantitative evaluation of Y-PET/CT and Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization.

Kappadath S, Henry E, Lopez B, Mahvash A Med Phys. 2024; 51(9):6061-6074.

PMID: 38781554 PMC: 11731408. DOI: 10.1002/mp.17175.

A comparison of methods for in vivo activity and absorbed dose quantification with PET/CT following yttrium-90 radioembolization.

Henry E, Mahvash A, Lopez B, Kappadath S Med Phys. 2024; 51(9):6034-6045.

PMID: 38772046 PMC: 11489031. DOI: 10.1002/mp.17174.

Single-Compartment Dose Prescriptions for Ablative Y-Radioembolization Segmentectomy.

Kappadath S, Lopez B Life (Basel). 2023; 13(6).

PMID: 37374021 PMC: 10303682. DOI: 10.3390/life13061238.

References

Elschot M, Lam M, van den Bosch M, Viergever M, W A M de Jong H . Quantitative Monte Carlo-based 90Y SPECT reconstruction. J Nucl Med. 2013; 54(9):1557-63. DOI: 10.2967/jnumed.112.119131. View

Pardo F, Sangro B, Lee R, Manas D, Jeyarajah R, Donckier V . The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Ann Surg Oncol. 2017; 24(9):2465-2473. DOI: 10.1245/s10434-017-5950-z. View

Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C . The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010; 51(8):1206-12. DOI: 10.2967/jnumed.109.074559. View

Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J . Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2002; 12(12):1711-20. DOI: 10.1023/a:1013569329846. View

Ricke J, Klumpen H, Amthauer H, Bargellini I, Bartenstein P, De Toni E . Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019; 71(6):1164-1174. DOI: 10.1016/j.jhep.2019.08.006. View

Gibbs P, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M . Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clin Colorectal Cancer. 2018; 17(4):e617-e629. DOI: 10.1016/j.clcc.2018.06.001. View

Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y . Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol. 2014; 9:26. PMC: 3904195. DOI: 10.1186/1748-717X-9-26. View

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J . Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010; 28(23):3687-94. DOI: 10.1200/JCO.2010.28.5643. View

Gulec S, Siegel J . Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med. 2007; 48(12):2080-6. DOI: 10.2967/jnumed.107.045443. View

10.

Liu D, Salem R, Bui J, Courtney A, Barakat O, Sergie Z . Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005; 16(7):911-35. DOI: 10.1097/01.RVI.0000164324.79242.B2. View

11.

Van Hazel G, Pavlakis N, Goldstein D, Olver I, Tapner M, Price D . Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009; 27(25):4089-95. DOI: 10.1200/JCO.2008.20.8116. View

12.

Dewaraja Y, Chun S, Srinivasa R, Kaza R, Cuneo K, Majdalany B . Improved quantitative Y bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling. Med Phys. 2017; 44(12):6364-6376. PMC: 5734647. DOI: 10.1002/mp.12597. View

13.

Dezarn W, Cessna J, DeWerd L, Feng W, Gates V, Halama J . Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011; 38(8):4824-45. DOI: 10.1118/1.3608909. View

14.

Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F . EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011; 38(7):1393-406. DOI: 10.1007/s00259-011-1812-2. View

15.

Dittmann H, Kopp D, Kupferschlaeger J, Feil D, Groezinger G, Syha R . A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors. J Nucl Med. 2018; 59(9):1366-1372. DOI: 10.2967/jnumed.117.205203. View

16.

Siman W, Mawlawi O, Mourtada F, Kappadath S . Systematic and random errors of PET-based Y 3D dose quantification. Med Phys. 2020; 47(6):2441-2449. DOI: 10.1002/mp.14117. View

17.

Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R . Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol. 2013; 24(11):1743-5. DOI: 10.1016/j.jvir.2013.07.011. View

18.

Helling T, Martin M . Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol. 2013; 21(2):501-6. DOI: 10.1245/s10434-013-3297-7. View

19.

Sofocleous C, Garcia A, Pandit-Taskar N, Do K, Brody L, Petre E . Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2013; 13(1):27-36. DOI: 10.1016/j.clcc.2013.11.010. View

20.

McGowan S, Burnet N, Lomax A . Treatment planning optimisation in proton therapy. Br J Radiol. 2012; 86(1021):20120288. PMC: 4651068. DOI: 10.1259/bjr.20120288. View